What is the role of SGLT2 inhibitors in patients with chronic kidney disease and HFrEF?
SGLT2 inhibitors have been shown to reduce the risk of renal disease progression and the composite of CV death or worsening HF in patients with HFrEF, regardless of whether they have T2D. Dapagli ozin has been approved for this indication, and the role of empagli ozin is currently under review by the Food and Drug Administration. In addition, SGLT2 inhibitors have been shown to slow the decline of kidney function in patients with chronic kidney disease, independent of the presence of diabetes.